复方黄黛片联合全反式维甲酸治疗非高危急性早幼粒细胞白血病:随机对照试验方案
本研究为多中心随机对照试验,非劣效设计,入组非高危急性早幼粒细胞白血病患者,诱导治疗均采用全反式维甲酸(ATRA)联合三氧化二砷(ATO),达血液学完全缓解后按1:1随机接受ATRA联合复方黄黛片(RIF)或ATRA联合ATO巩固治疗,旨在比较疗效并评估口服RIF能否减少住院天数和医疗费用。
要点
- 非高危APL诱导治疗均用ATRA联合ATO,缓解后随机比较ATRA-RIF与ATRA-ATO巩固疗效。
- 试验为非劣效设计,若证实非劣效则进一步探索优效性。
- 口服RIF可能减少住院天数和医疗费用,但需本试验验证。
核心结论
- 本试验旨在比较ATRA-ATO与ATRA-RIF在非高危APL患者中的疗效,并验证口服RIF能否减少总住院天数和医疗费用。
研究设计与样本
- 多中心随机对照试验,非劣效设计,若证实非劣效则探索优效性。
- 所有患者诱导治疗均接受ATRA-ATO,达血液学完全缓解后按1:1随机分为ATRA-RIF组(试验组)和ATRA-ATO组(对照组)。
关键数值与推荐
- 巩固治疗期间,两组分别接受ATRA联合RIF或静脉ATO,用药2周、停药2至约4周,直至分子学完全缓解。
- 达分子学完全缓解后,继续ATRA联合口服RIF,用药2周、停药2至约4周,共6个疗程。
临床怎么用
- 口服RIF给药途径较静脉ATO更方便,若验证非劣效,可能为 non-high-risk APL 巩固治疗提供便利方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute promyelocytic leukemia (APL) is a highly curable disease when treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO). The combination of ATO and ATRA has become the standard therapeutic protocol for induction therapy in non-high-risk APL. An oral arsenic realgar-indigo naturalis formula (RIF) has also showed high efficacy and it has a more convenient route of administration than the standard intravenous regimen. Unlike in previous trials, the arsenical agent was used simultaneously with ATRA during post-remission therapy in this trial. METHODS: This study was designed as a multicenter, randomized controlled trial. The trial has a non-inferiority design with superiority being explored if non-inferiority is identified. All patients receive ATRA-ATO during the induction therapy. After achieving hematologic complete remission (HCR), patients were randomly assigned (1:1) to receive treatment with ATRA-RIF (experimental group) or ATRA-ATO (control group) as the consolidation therapy. During the consolidation therapy, the two groups receive ATRA plus RIF or intravenous ATO 2 weeks on and 2 to ~ 4 weeks off until molecular complete remission (MCR), then ATRA and oral RIF 2 weeks on and 2 to ~ 4 weeks off giving a total of six courses. DISCUSSION: This trial aims to compare the efficacy of ATRA-ATO versus ATRA-RIF in non-high-risk patients with APL, to demonstrate that oral RIF application reduces the total hospitalization days and medical costs. The simple schedule was studied in this trial. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02899169. Registered on 14 September 2016.
引用
- Zhang X, Liu L, Yao Y, et al. Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial. Trials. 2020. PMID: 31898521. doi:10.1186/s13063-019-3983-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。